Based on these results, we hypothesized that increased TGFβ‐SMAD signaling in mesenchymal‐type lung cancer cells after doxorubicin treatment potentiates YAP‐dependent AXL expression. The gene discussed is TGFB1; the disease is lung carcinoma.